62717-74-2

Upstream product

• 6388-72-3 2-(4-methoxyphenyl)oxirane 
• 120-20-7 2-(3,4-dimethoxyphenyl)-ethylamine 
• 13305-14-1 methyl 2-hydroxy-2-(4-methoxyphenyl)acetate 
• 104422-01-7 N-<2-hydroxy-2-(4-methoxyphenyl)ethyl>-2-(3,4-dimethoxyphenyl)acetamide 
• 160852-21-1 N-(3,4-dimethoxyphenethyl)-2-hydroxy-2-(4-methoxyphenyl)acetamide 
• 20714-90-3 4-Methoxymandelic acid 
• 32953-13-2 3,4-dimethoxy-phenylethylamine 
• 10313-60-7 3,4-dimethoxyphenylacetyl chloride 
• 33646-40-1 4-methoxymandelonitrile 
• 93-40-3 (3,4-Dimethoxyphenyl)acetic acid 
• 55275-61-1 2-amino-1-(4-methoxyphenyl)ethanol 

Downstream Products

• 63697-91-6 denopamine 
• 87081-60-5 5-{2-[2-(3,4-Dimethoxy-phenyl)-ethylamino]-1-hydroxy-ethyl}-2-methoxy-phenol 
• 104421-93-4 7,8-Dimethoxy-1-(4-methoxy-phenyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine 
• 62717-75-3 SKF 76321 hydrobromide 
• 104421-95-6 N-allyl-2,3,4,5-tetrahydro-1-(4-hydroxyphenyl)-1H-3-benzazepine-7,8-diol hydrobromide 
• 104421-94-5 3-Allyl-7,8-dimethoxy-1-(4-methoxy-phenyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine 

Relevant academic research and scientific papers

Primary alkylboronic acids as highly active catalysts for the dehydrative amide condensation of α-hydroxycarboxylic acids

Primary alkylboronic acids such as methylboronic acid and butylboronic acid are highly active catalysts for the dehydrative amide condensation of α-hydroxycarboxylic acids. The catalytic activities of these primary alkylboronic acids are much higher than those of the previously reported arylboronic acids. The present method was easily applied to a large-scale synthesis, and 14 g of an amide was obtained in a single reaction.

Dopamine Agonists Related to 3-Allyl-6-chloro-2,3,4,5-tetrahydro-1-(4-hydroxyphenyl)-1H-3-benzazepine-7,8-diol. 6-Position Modifications

The N-allyl derivative (SK and F 85174) of 6-chloro-2,3,4,5-tetrahydro-1-(4-hydroxyphenyl)-1H-3-benzazepine-7,8-diol (SK and F 82526) retains the DA-1 agonist potency of the latter compound but unlike the parent also shows substantial DA-2 agonist activity.In a previous study of N-substituted benzazepines these combined agonist effects were shown to be uniquely associated with the N-allyl group.A continuation of this research has examined dependency of combined DA-2/DA-1 agonist activities on 6=position modification with the specific objective of developing an agonist with maximum effectiveness and potency at the DA-2 receptor subtype.DA-2 agonist activity was measured in a rabbit ear artery assay, and DA-1 agonist activity was determined in an adenylate cyclase assay.Replacing chloro with bromo retains the activity pattern and the potency of the chloro compound: replacement with a hydrogen causes a decrease of both DA-1 and DA-2 receptor activating potency.Introduction of a 6-methyl group causes loss of DA-2 agonist activity and reduction in DA-1 agonist potency.Substitution with a 6-fluoro provides the best balance of DA-2 and DA-1 agonist activities; this compound was moderately in both assays.

2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINE-7,8-DIONES

Novel benzazepine derivatives having central and peripheral dopaminergic activity useful in treating Parkinson's and cardiovascular diseases. The compounds have additional use as intermediates for the synthesis of other benzazepines with similar useful properties. The 1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-dione derivatives are particularly useful.

PHARMACEUTICAL COMPOSITIONS AND METHODS INVOLVING BENZAZEPINE DERIVATIVES

Pharmaceutical compositions and a method of stimulating peripheral dopamine receptors by administering internally a nontoxic effective quantity of a benzazepine derivative to an animal. Renal vasodilator and diuretic methods are also disclosed.